1361970-55-9

Upstream product

• 1083326-75-3 N-[2-(methyloxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-pyridinyl]methanesulfonamide 
• 1361970-57-1 5-bromo-2-methoxypyridin-3-amine hydrochloride 
• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 1254036-80-0 6-chloro-1-(phenylsulfonyl)-4-(trimethylstannanyl)-1H-indazole 
• 1254036-94-6 6-chloro-4-iodo-1-(phenylsulfonyl)-1H-indazole 
• 885519-56-2 6-chloro-4-iodo-1H-indazole 
• 1254036-85-5 6-chloro-4-(5-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1-(phenylsulfonyl)-1H-indazole 
• 1361970-56-0 potassium {6-(methoxy)-5-[(methylsulfonyl)amino]-3-pyridinyl}trifluoroborate 
• 1254036-84-4 4-[5-(bromomethyl)-1,3-oxazol-2-yl]-6-chloro-1-(phenylsulfonyl)-1H-indazole 
• 1254036-83-3 {2-[6-chloro-1-(phenylsulfonyl)-1H-indazol-4-yl]-1,3-oxazol-5-yl}methanol 
• 1254036-81-1 ethyl 2-[6-chloro-1-(phenylsulfonyl)-1H-indazol-4-yl]-1,3-oxazole-5-carboxylate 
• 1083327-58-5 N-[5-bromo-2-(methyloxy)-3-pyridinyl]methanesulfonamide 
• 884495-39-0 5-bromo-2-(methyloxy)-3-pyridinamine 
• 152684-30-5 5-bromo-2-methoxy-3-nitropyridine 

Downstream Products

• 1361970-34-4 N-[5-[4-(5-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide tosylate salt 
• 1361970-37-7 N-[5-[4-(5-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide mesitylenesulfonate salt 

Relevant academic research and scientific papers

Development of Flexible and Scalable Routes to Two Phosphatidinylinositol-3-kinase Delta Inhibitors via a Common Intermediate Approach

This paper describes the discovery and development of a flexible route to two candidate drug molecules by a common intermediate approach. Key reactions include Negishi and Suzuki couplings to form biaryl bonds. Conditions for a Miyaura borylation of heteroaryl bromides were also developed. Heteroaryl trifluoroborates and aryl chlorides were used as coupling partners in the Suzuki reaction, thereby minimizing detrimental side reactions such as protodeboronation and oxidative homocoupling. A complementary set of reaction conditions using pinacolboronates with potassium bifluoride as an additive were also developed and used to make 5 kg of drug substance for use in early-phase clinical trials.

Indazole derivatives for use in the treatment of influenza virus infection

The present invention is directed to compounds for use in the treatment or prevention of influenza virus infection.

Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease

Optimization of lead compound 1, through extensive use of structure-based design and a focus on PI3Kδ potency, isoform selectivity, and inhaled PK properties, led to the discovery of clinical candidates 2 (GSK2269557) and 3 (GSK2292767) for the treatment of respiratory indications via inhalation. Compounds 2 and 3 are both highly selective for PI3Kδ over the closely related isoforms and are active in a disease relevant brown Norway rat acute OVA model of Th2-driven lung inflammation.

POLYMORPHS AND SALTS OF N- [5- [4- (5- { [(2R,6S) -2, 6 - DIMETHYL - 4 -MORPHOLINYL] METHYL} - 1, 3 - OXAZOL - 2 - YL) - 1H- INDA ZOL-6-YL] -2- (METHYLOXY) - 3 - PYRIDINYL] METHANESULFONAMIDE

The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.